SCIEX, a global leader in life science analytical technologies, and a company of Danaher Corporation, has launched the RNA 9000 Purity & Integrity kit, for the BioPhase 8800 system and the PA 800 Plus system.
As genomic medicine takes center stage, and the demand for RNA-based therapies and vaccines rises, the integrity and quality of RNA species is becoming increasingly important. Scientists have been faced with difficult methods that have poor resolution and transferability, which they are able to work to improve therapeutic drug development and meet critical timelines. For intact mRNA analysis, scientists need validated, production-ready methods and instrument platforms that allow them to confidently distinguish desired therapeutic substances from unwanted impurities.
This RNA 9000 Purity and Integrity kit is a purpose-built high resolution analysis technique for therapeutics. It was specifically designed to provide significantly higher resolution for a wide variety of therapeutically relevant mRNA classes, from 50 to 9,000 bases.
This kit, according to Jeremie Parot, has the potential and capability to revolutionize the analysis of mRNA therapies and vaccines. Not only can it be used for final product quality control to assess quality and length post nanoparticle or viral vector encapsulation, but it can also be used during early-stage development immediately following IVT (in-vitro transcribe) to ensure the safety and size of the mRNA payload is what the researchers are targeting.
According to Susan Darling, the ability to assist biopharmaceutical developers in accelerating the development of RNA-based medicines and bridge the development gap has enabled scientists to do so in a 21cfr part 11b compatible manner, across applications and locations.
Scientists may expect to:
Reduce time to market with exceptional reproducibility, experiment to experiment Estimate a target therapeutic size Experiment with minimal sample material and have the ability to detect low level impurities present in samples